Tislelizumab plus chemotherapy significantly improved OS in patients with advanced esophageal cancer
Novartis announced a significant improvement in the overall survival with tislelizumab plus chemotherapy in patients with advanced esophageal cancer.
The company announced the primary endpoint at the interim analysis of the RATIONALE 306 trial, in which tislelizumab plus chemotherapy significantly improved the overall survival compared to chemotherapy alone in patients with advanced, previously untreated, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), irrespective of PD-L1 expression.
RATIONALE 306 (NCT03783442) is a Phase 3 clinical trial that enrolled 649 participants and randomized in the 1:1 to receive tislelizumab plus chemotherapy vs. chemotherapy alone. Overall survival was considered the primary endpoint.